Successful treatment of severe COVID-19 with subcutaneous anakinra as a sole treatment

Saved in:
Bibliographic Details
Published inRheumatology (Oxford, England) Vol. 59; no. 8; pp. 2171 - 2173
Main Authors González-García, Andrés, García-Sánchez, Isabel, Lopes, Vanessa, Moreno-Arrones, Oscar Muñoz, Tortosa-Cabañas, Marina, Elías-Sáenz, Isabel, Hernández-Rodríguez, José
Format Journal Article
LanguageEnglish
Published England Oxford University Press 01.08.2020
Subjects
Betacoronavirus
Coronavirus Infections - drug therapy
COVID-19
Humans
Injections, Subcutaneous
Interleukin 1 Receptor Antagonist Protein - administration & dosage
Interleukin 1 Receptor Antagonist Protein - therapeutic use
Letters to the Editor
Male
Middle Aged
Pandemics
Pneumonia, Viral - drug therapy
SARS-CoV-2
Treatment Outcome
Online AccessGet full text

Cover

More Information
ISSN:1462-0324
1462-0332
DOI:10.1093/rheumatology/keaa318